InvestorsHub Logo
Followers 4
Posts 388
Boards Moderated 0
Alias Born 10/28/2013

Re: Whalatane post# 262760

Monday, 04/06/2020 2:06:31 AM

Monday, April 06, 2020 2:06:31 AM

Post# of 430247
Whal:

"IMHO in the end it wont be 3 generics ... Teva is a $16B a yr co with established " fish oil " supply and marketing chain since they sell G Lovaza. They will sell G Vascepa at a loss if necessary for a yr or two to drive the other generics out."

You're dreaming.

I'm a TEVA shareholder, both previously (and took a big 20% loss) and more recently (when Buffet bought in, and again at recent lows).

I believe in both AMRN (still) and TEVA but you're off your rocker if you think TEVA as a company is in a position to sell any drug (let alone a volume play) at a loss and subsidize 2 years to "drive other generics out".

https://www.ft.com/content/794dce40-4db9-11ea-95a0-43d18ec715f5

This is a company that has massive net debt and is just emerging from years of losses out of some bad management decisions. They have a good CEO (hopefully we turf out JT and get someone similar in) but one who's under immense pressure to turn things around and increase gross margins.

They are NOT in a position to do an UBER or AMZN and subsidize huge losses for years.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News